Peer Review #3 of "Efficacy of a new dietary supplement in dogs with advanced chronic kidney disease (v0.1)"

2020 ◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Peer Review ◽  
Dietary Supplement ◽  
Advanced Chronic Kidney Disease

scholarly journals Efficacy of a new dietary supplement in dogs with advanced chronic kidney disease

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9663
Author(s):  
Elisa Martello ◽  
Francesca Perondi ◽  
Maria Teresa Capucchio ◽  
Ilaria Biasato ◽  
Elena Biasibetti ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Dietary Supplement ◽  
Control Group ◽  
Common Disease ◽  
Creatinine Ratio ◽  
Serum Bicarbonate ◽  
Phosphorus Level ◽  
Urine Protein ◽  
Advanced Chronic Kidney Disease

Chronic kidney disease (CKD) is a common disease in elderly dogs. The present study aims to evaluate the efficacy of a dietary supplement containing calcium carbonate, calcium-lactate gluconate, chitosan and sodium bicarbonate in dogs with IRIS stage 3 of CKD. Twenty dogs were enrolled in the study, ten were administered the new dietary supplementation for 180 days (T group) while the others were used as control group (C group). Haematologic, biochemical and urinalysis were performed every 30 days. A significant reduction in the T group compared to the C group in serum phosphorus level and increase in serum bicarbonate and ionized calcium values were recorded. The urine protein-to-creatinine ratio (UPC) was significantly lower in the T group at the end of the study compared to the C group. The tested supplement could be considered as a supportive treatment for dogs with advanced CKD.

Phosphate binders in patients with chronic kidney disease: Between the new and the old.

2019 ◽  
pp. 2-3
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Estimated Glomerular Filtration Rate ◽  
Chronic Kidney Disease Stage ◽  
Disease Stage ◽  
Phosphate Binders ◽  
Advanced Chronic Kidney Disease ◽  
Phosphate Retention ◽  
Stage 4 ◽  
Dietary Phosphate

Impaired phosphate excretion by the kidney leads to Hyperphosphatemia. It is an independent predictor of cardiovascular disease and mortality in patients with advanced chronic kidney disease (stage 4 and 5) particularly in case of dialysis. Phosphate retention develops early in chronic kidney disease (CKD) due to the reduction in the filtered phosphate load. Overt hyperphosphatemia develops when the estimated glomerular filtration rate (eGFR) falls below 25 to 40 mL/min/1.73 m2. Hyperphosphatemia is typically managed with oral phosphate binders in conjunction with dietary phosphate restriction. These drugs aim to decrease serum phosphate by binding ingested phosphorus in the gastrointestinal tract and its transformation to non-absorbable complexes [1].

Sign in / Sign up

Export Citation Format

Share Document